AIM ImmunoTech in pact for planning of proposed Ampligen trial

AIM ImmunoTech in pact for planning of proposed Ampligen trial

AIM ImmunoTech Advances Pancreatic Cancer Trial with Key Milestones

AIM ImmunoTech Inc. (NYSE American: AIM) has outlined key milestones for its ongoing Phase 2 clinical trial, DURIPANC, evaluating Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for metastatic pancreatic cancer. The trial, a collaboration with Erasmus Medical Center (Erasmus MC) in the Netherlands, aims to enroll up to 25 patients and assess the safety and efficacy of the combination therapy in post-chemotherapy settings according to the company's announcement.

Planned milestones include completing enrollment by July 2026 and full Ampligen dosing by August 2026. Primary endpoint evaluation—clinical benefit rate (stable disease, partial response, or complete response at six months)—is scheduled for December 2026. Secondary endpoints, including progression-free survival, overall survival, and immune profiling, will be analyzed by June 2027 as reported. Interim updates, such as the February 2026 report, highlight continued promising Progression-Free Survival and Overall Survival from Phase 1, with no significant toxicity reported to date according to interim data.

AIM emphasizes the trial's alignment with its strategic focus on advancing Ampligen toward a Phase 3 trial. The company holds orphan drug designations in the U.S. and EU for pancreatic cancer, granting market exclusivity post-approval, and a U.S. patent for Ampligen's combination with anti-PD-L1 therapies, extending protection to 2039 as stated. These intellectual property and regulatory advantages are positioned to enhance the drug's commercial potential, particularly in a market where oncology therapies in late-stage trials often attract significant M&A interest according to industry analysis.

While interim data from the trial indicate improved quality of life and immune system activation, AIM cautions that clinical success does not guarantee regulatory approval. The company's filings note risks, including trial delays, regulatory hurdles, and uncertainties in extrapolating preclinical results to humans as detailed.

With detailed data expected later in 2026, stakeholders will closely monitor outcomes as AIM seeks to validate Ampligen's role in addressing a high-unmet-need oncology market.